AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
Go back to AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer| Bay National Corporation (AMEX: BAYN) | Delayed: 0.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.01 | 52 Week High | $0.04 | |||
| Open | $61.11 | 52 Week Low | $0.03 | |||
| Day High | $0.01 | P/E | 0.00 | |||
| Day Low | $0.01 | EPS | $-8.34 | |||
| Volume | 358,028 | |||||
| Bay National Corporation (AMEX: BAYN) | Delayed: 0.01 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.01 | 52 Week High | $0.04 | |||
| Open | $61.11 | 52 Week Low | $0.03 | |||
| Day High | $0.01 | P/E | 0.00 | |||
| Day Low | $0.01 | EPS | $-8.34 | |||
| Volume | 358,028 | |||||
| Bayer Aktiengesellschaft American Depositary Shares (AMEX: BAYRY) | Delayed: 10.44 +0.04 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.40 | 52 Week High | $135.54 | |||
| Open | $10.36 | 52 Week Low | $94.36 | |||
| Day High | $10.49 | P/E | N/A | |||
| Day Low | $10.30 | EPS | $0.00 | |||
| Volume | 614,627 | |||||
| Bayer AG (AMEX: BAYZF) | Delayed: 41.84 +0.48 (1.16%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.36 | 52 Week High | $135.00 | |||
| Open | $41.66 | 52 Week Low | $94.95 | |||
| Day High | $41.84 | P/E | N/A | |||
| Day Low | $41.66 | EPS | $0.00 | |||
| Volume | 3,019 | |||||

